Back to top
more

Cara Therapeutics, Inc. (CARA)

(Delayed Data from NSDQ)

$19.13 USD

19.13
344,803

-0.56 (-2.84%)

Updated Oct 18, 2019 03:56 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | C Growth | D Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 4.92% and 1.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CARA

Zacks Equity Research

Cara Shares Up on Positive Phase III Data for Itchiness Drug

Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

FMS CARA PCRX MNK

Zacks Equity Research

Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CARA

Zacks Equity Research

Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

CARA

Zacks Equity Research

Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 11.86% and 65.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

CARA

Zacks Equity Research

Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?

During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.

ATHX CATB CARA TLRY

Zacks Equity Research

Is a Beat in Store for Catabasis (CATB) This Earnings Season?

Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

NVAX CARA CATB TLRY

Zacks Equity Research

Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?

Management at Cooper Companies (COO) expects solid contributions from CVI and CSI units.

CARA COO CHS AZUL

Zacks Equity Research

What's in Store for Vericel (VCEL) This Earnings Season?

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

BDSI ADRO CARA VCEL

Zacks Equity Research

Cara (CARA) Up on IDMC's Recommendation to Continue Trial

Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.

FMS CARA PCRX MNK

Zacks Equity Research

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -10.87% and 7.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CARA

Zacks Equity Research

The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

STZ DEO GWPH CARA CRON

Sweta Killa

ETFs & Stocks to Tap Marijuana Boom

Investors seeking to tap the ongoing green rush may consider these ETFs and stocks.

DEO STZ HEINY GWPH CARA CGC CRON ACT MJ

Zacks Equity Research

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CARA

Zacks Equity Research

Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

GILD CELG AMGN CARA KERX XLRN AKBA

Zacks Equity Research

Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

CARA

Zacks Equity Research

Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)

Cara Therapeutics (CARA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

CARA

Megan Sanks

Here's Why Cara Therapeutics (CARA) Shares Plummeted 31% Today

Shares of Cara Therapeutics (CARA) nosedived 31% Friday in morning trading after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.

CARA

Zacks Equity Research

Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session

Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day

EXEL CARA

Zacks Equity Research

Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

Investors in Cara Therapeutics (CARA) need to pay close attention to the stock based on moves in the options market lately.

CARA

Megan Sanks

Cara Therapeutics (CARA) Stock Rises After Cr845 Trial Update

Cara Therapeutics, Inc. (CARA) shares gained 10% in late morning trading following the recent evaluation of its trial for Cr845.

CARA

Sweta Killa

5 Top Performing Stocks of the Best ETF of Q1

Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.

BBC TGTX GBT CARA

Zacks Equity Research

Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%

Cara Therapeutics, Inc. (CARA) shares rose above 5% in the last trading session.

ANTH CARA

Zacks Equity Research

Are Options Traders Betting on a Big Move in Cara Therapeutics, Inc. (CARA) Stock?

Investors in Cara Therapeutics, Inc. (CARA) need to pay close attention to the stock as it has some of the highest implied volatility of all equity options today.

CARA

Zacks Equity Research

Cara Therapeutics (CARA) Worth Watching: Stock Jumps 8%

Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares climb over 8% on the day.

EXAS CARA